Submit A Case CPMS
Home - Network - Working Groups - Rare Disease Working Groups - Heritable Thoracic Aortic Diseases (HTAD-WG) - Clinical Decision Support Tools - Clinical Expert Consensus Statements Written
Heritable Thoracic Aortic Diseases (HTAD-WG)
Introduction
Disease Information
Overview Genetic Testing for Hereditary Thoracic Aortic Aneurysm Disease Familial Thoracic Aortic Aneurysm and Dissection (Familial TAAD) Marfan Syndrome
Experts & Centers
Experts Centers
Clinical Decision Support Tools
Patient Pathways Do’s and Don’ts Clinical Practice Guidelines (CPGs) adopted Clinical Expert Consensus Statements Written Outcome Measures
Registry
Research
Clinical Trials/Observational Studies Research Publications
Training and Education
E-Learning Pills of Knowledge (PoK) Webinars
Sub Working Groups
Aortic Imaging Gene Compendium Pediatrics Variants

Clinical Expert Consensus Statements Written

The Heritable Thoracic Aortic Diseases Working Group (HTAD-WG) have developed consensus statements drawing from the latest research and clinical data to provide evidence-based recommendations for the diagnosis, treatment and management of these diseases.

Results (3)
Consensus statement of the VASCERN HTAD Working Group (January 23, 2019)
March 20 2023

In patients with HTAD, Fluoroquinolones should be used with caution because of a possible risk for exacerbation of aortic disease.  The use of alternatives is preferred while awaiting further evidence.

Consensus statement for the screening and management of patients with pathogenic ACTA2 variants (November 21, 2019)
March 20 2023

Ingrid M. B. H. van de Laar, Eloisa Arbustini, Bart Loeys, Erik Björck, Lise Murphy, Maarten Groenink, Marlies Kempers, Janneke Timmermans, Jolien Roos-Hesselink, Kalman Benke, Guglielmina Pepe, Barbara Mulder, Zoltan Szabolcs, Gisela Teixidó-Turà, Leema Robert, Yaso Emmanuel, Arturo Evangelista, Alessandro Pini, Yskert von Kodolitsch, Guillaume Jondeau, Julie De Backer. European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants. Orphanet J Rare Dis 14,264 (2019) doi:10.1186/s13023-019-1186-2

VASCERN Heritable Thoracic Aortic Diseases (HTAD) Working Group statement on COVID-19 (March 2020)
January 03 2023
Skip to content